Related Experiment Video
Updated: Jul 13, 2026
04:11
Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA
Published on: December 15, 2023
[Relationship between hepatitis B virus genotypes and liver fibrosis]
Yue-hua Huang1, Zhi-jian Yu, Cheng Wang
1Hepatology Unit and Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Summary
Hepatitis B virus (HBV) genotype C is linked to more severe liver damage than genotype B. This finding highlights genotype C as a risk factor for advanced liver fibrosis in patients with chronic hepatitis B.
Area of Science:
- Hepatology
- Virology
- Biochemistry
Context:
- Hepatitis B virus (HBV) infection is a global health concern.
- Liver fibrosis is a key pathological process in chronic liver diseases.
- Understanding HBV genotype-specific disease progression is crucial for patient management.
Purpose:
- To investigate the association between different hepatitis B virus genotypes and the progression of liver fibrosis.
- To analyze the correlation of HBV genotypes with serum fibrosis markers and albumin-globulin ratio.
Summary:
- A study of 298 HBV-infected patients in Guangdong province identified HBV genotypes B and C as dominant.
- Patients with HBV genotype C exhibited significantly higher serum fibrosis indices and a lower albumin-globulin ratio compared to genotype B patients.
- These findings suggest that HBV genotype C is associated with more severe liver injury.
Impact:
- This research provides valuable insights into genotype-specific pathogenicity of HBV.
- It may inform clinical strategies for monitoring and managing patients with HBV genotype C infection.
- Highlights the need for genotype-specific treatment considerations in HBV-related liver disease.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:23Cirrhosis I: Introduction
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...